A new trading day began on Friday, with Standard BioTools Inc (NASDAQ: LAB) stock price up 3.33% from the previous day of trading, before settling in for the closing price of $1.2. LAB’s price has ranged from $0.92 to $2.25 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 11.61% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 60.26%. With a float of $368.40 million, this company’s outstanding shares have now reached $383.61 million.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 4.20%, while institutional ownership is 72.49%. The most recent insider transaction that took place on Nov 12 ’25, was worth 445,838. In this transaction Director of this company bought 375,000 shares at a rate of $1.19, taking the stock ownership to the 62,050,000 shares. Before that another transaction happened on Nov 11 ’25, when Company’s Director bought 300,000 for $1.20, making the entire transaction worth $358,800. This insider now owns 61,675,000 shares in total.
Standard BioTools Inc (LAB) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.05 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.89% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Here are Standard BioTools Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.8 million. That was better than the volume of 1.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 75.69%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 35.48%, which indicates a significant decrease from 62.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0754 in the past 14 days, which was lower than the 0.0771 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2878, while its 200-day Moving Average is $1.2248. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.2800. Second resistance stands at $1.3200. The third major resistance level sits at $1.3800. If the price goes on to break the first support level at $1.1800, it is likely to go to the next support level at $1.1200. The third support level lies at $1.0800 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
With a market capitalization of 476.86 million, the company has a total of 384,565K Shares Outstanding. Currently, annual sales are 174,430 K while annual income is -138,890 K. The company’s previous quarter sales were 19,550 K while its latest quarter income was -34,690 K.
